Europe’s leading stem cell storage bank lists on NYSE Euronext

Amsterdam, October 22, 2009 – Dutch-based leading European stem cell storage bank, Cryo-Save Group N.V. (NYSE Euronext: CRYO) completed its listing on NYSE Euronext’s Amsterdam market today.

Cryo-Save has storage and processing facilities in 5 countries and is operating in 38 countries in Europe, Asia and Africa. With over 115.000 samples stored, Cryo-Save is Europe’s largest adult stem cell storage bank. The company sets the highest quality standards in stem cell storage, as it aims to make an important contribution to conquer possible life-threatening diseases for children and adults in the future. The company is committed to further improve stem cell cryo-preservation techniques, by participating in European Commission funded projects, in Universities and Hospitals.

Cryo-Save shares trade on NYSE Euronext under the symbol “CRYO” and are denominated in Euros. After opening, the first market price was € 6.30 per share. Based on the total number of 9,639,191 shares the total market capitalization of the company at opening price was € 60,726,903.

Marc Waeterschoot, Chief Executive, commented: “Being a Dutch company, with most of our business on the continent, a listing on NYSE Euronext’s European market should increase our visibility as well as liquidity and will therefore add value to the company and to the shareholders that have invested in us since our listing on AIM in London in 2007.”

“We welcome Cryo-Save to NYSE Euronext’s European market, the largest and most liquid market in Europe. As a leading stem cell storage bank in Europe the company will gain unmatched access to investors in the eurozone.”, said Joost van der Does de Willebois, CEO of Euronext Amsterdam. 

Media contacts:

NYSE Euronext (Amsterdam):
Alice Jentink                             +31 (0)20 5504488       

Cryo-Save Group NV:
Arnoud van Tulder (CFO)            +31 (0)575 548998

About Cryo-Save N.V.
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world.  Driven by its international business strategy, Cryo-Save is now represented in 38 countries on three continents and has state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France (under construction).

Cryo-Save sets the highest quality standards in stem cell storage, as it aims to make an important contribution to conquer possible life-threatening diseases in the future. As a service to the public, Cryo-Save offers a Cost-free Family Donation Programme, free of charge, to families wishing to store their newborn's umbilical cord blood stem cells for a family member diagnosed with a life-threatening disease treatable by stem cells. The company is committed to further improve stem cell cryopreservation techniques, by participating in European Commission funded projects, in Universities and Hospitals.

About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies.  The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products.  With more than 8,000 listed issues, NYSE Euronext's equities markets -- the New York Stock Exchange, NYSE Euronext, NYSE Amex and NYSE Alternext, as well as NYSE Arca -- represent nearly 40 percent of the world's equities trading, the most liquidity of any global exchange group.  NYSE Euronext also operates NYSE Liffe, the leading European derivatives business and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies.  NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500.  For more information, please visit: http://www.nyx.com

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext’s plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext’s results to differ materially from current expectations include, but are not limited to: NYSE Euronext’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext’s reference document for 2008 (“document de référence”) filed with the French Autorité des Marchés Financiers (Registered on April 28, 2009 under No. R. 09-031), 2008 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.